CompletedPhase 2NCT00003334
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU Langone Health
- Principal Investigator
- Franco M. Muggia, MDNYU Langone Health
- Intervention
- paclitaxel(drug)
- Eligibility
- 120 years · FEMALE
- Timeline
- 1997
Study locations (5)
- NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
- New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
- Mount Sinai Medical Center, NY, New York, New York, United States
- Albert Einstein Comprehensive Cancer Center, The Bronx, New York, United States
- New York Medical College, Valhalla, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003334 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.